Sales hit $7.7 billion with 11.6% growth, but EBITDA guidance fell on cost pressures.

Medline Inc (MDLN) raises organic sales guidance to 9%-10% while navigating inflationary pressures and operational investments to support record customer demand.

Medline (NASDAQ:MDLN) reported second-quarter 2026 net sales growth of 12% to $7.7 billion, supported by demand across its medical-surgical product and supply-chain businesses, while raising its full-year organic sales outlook. The company also lowered its adjusted EBITDA guidance, citing operationa

Insulet stock crashed Wednesday after lowering sales guidance for its body-worn insulin pump, Omnipod, in the back half of the year.

Although the revenue and EPS for Medline (MDLN) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Investing.com -- Medline shares slumped more than 13% in premarket trading Wednesday after the medical supply distributor reported a 58.3% year-over-year drop in second-quarter net income, weighed down by losses tied to a fire that destroyed one of its distribution centers.

Ranpak (NYSE:PACK) reported second-quarter revenue growth driven by a sharp increase in automation equipment sales, while management said it remains on track to meet its full-year outlook and generate roughly $60 million in automation revenue in 2026. Chairman and CEO Omar Asali said automation rev

COO retirement and new client agreement put Medline (MDLN) in focus Medline (MDLN) is drawing investor attention after Chief Operating Officer Stephen L. Miller announced plans to retire for health-related reasons, and the company also signed a new Prime Vendor agreement with Allina Health. See our latest analysis for Medline. Recent news around the COO transition, the Allina Health agreement and new distribution capacity in California comes as Medline’s 30 day share price return is 8.76%,...